Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin, Sintilimab, and Capecitabine in HER2+ Gastric Cancer
NCT05113459Phase 2Unknown
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05113459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113459.